Cardioprotective efficacy of verapamil and mibefradil in young UM-X7.1 cardiomyopathic hamsters.
Since calcium overload and increased in T-type calcium channel activity have been observed in the cardiomyopathic (CM) hamster, we hypothesized that mibefradil (Ro 40-5967), a new T- and L-type calcium channel blocker, may exert significant cardioprotection in the early phase of the disease. Young (30-day-old) CM hamsters of the UM-X7.1 subline were treated with mibefradil or verapamil for 4 to 6 weeks. Mibefradil doses were in the range of 0.5 to 8 mg/kg/day while verapamil was given at a dose of 5-10 mg/kg/day, both drugs being injected twice daily (s.c. and i.p. alternatively). At the end of the treatment period, myocardial and skeletal muscle (tongue) were harvested and processed for assessment of necrotic changes and calcification. In hearts from control CM hamsters, numerous necrotic and calcified foci were observed. These myocardial necrosis markers were not attenuated by mibefradil in the dose range studied whereas verapamil significantly reduced their severity. The dystrophic process in skeletal muscle (tongue) was not inhibited by mibefradil or verapamil. These results suggest that mechanisms other than inhibition of T- and L-type calcium channels are related to the cardioprotection observed in the presence of verapamil. A specific action on the sarcoplasmic reticulum (ryanodine-sensitive calcium channel) or the mitochondria may explain the efficacy of phenylalkylamines (verapamil) in this condition.
Paquette
F
F
Département de Pharmacologie, Faculté de Médecine, Université de Montréal, QC, Canada.
Jasmin
G
G
Dumont
L
L
D000818:Animals; D015415:Biomarkers; D002114:Calcinosis / Q000473:pathology; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D009202:Cardiomyopathies / Q000188:drug therapy* / Q000473:pathology; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D006224:Cricetinae; D005260:Female; D006321:Heart / Q000187:drug effects; D008297:Male; D020748:Mibefradil / Q000627:therapeutic use*; D018482:Muscle, Skeletal / Q000187:drug effects / Q000473:pathology; D009206:Myocardium / Q000473:pathology; D009336:Necrosis; D013997:Time Factors; D014059:Tongue / Q000187:drug effects / Q000473:pathology; D014700:Verapamil / Q000627:therapeutic use*
D015415:Biomarkers; D002121:Calcium Channel Blockers; D002317:Cardiovascular Agents; D020748:Mibefradil; D014700:Verapamil